A. C. Barreto, N. Y. Maeda, R. P. Soares, C. Cícero, and A. A. Lopes, Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study, Brazilian Journal of Medical and Biological Research, vol.41, issue.8, pp.657-663, 2008.
DOI : 10.1590/S0100-879X2008000800003

J. Barst-robyn, V. Michael-mcgoon, V. Mclaughlin, R. Tapson, S. Oudiz et al., Beraprost therapy for pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.41, issue.12, pp.2119-2144, 2003.
DOI : 10.1016/S0735-1097(03)00463-7

J. Barst-robyn, A. Michael-mcgoon, O. Torbicki, M. J. Sitbon, H. Krowka et al., Diagnosis and differential assessment of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.40-47, 2004.
DOI : 10.1016/j.jacc.2004.02.032

B. Gérard, Hypertension artérielle pulmonaire de l'enfant, Cardiovascular Diseases Supplements, pp.126-131, 2010.

B. Heather, M. John, M. Dagle, J. M. Klein, K. K. Ryckman et al., Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn, Pediatric Research, vol.71, pp.162-167, 2012.

A. Chaouat, . Coulet, . Favre, . Simonneau, . Weitzenblum et al., Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension, Thorax, vol.59, issue.5, pp.446-448, 2004.
DOI : 10.1136/thx.2003.11890

C. Ari, L. Savale, C. Chouaid, L. Tu, . Benjamin et al., Role for Interleukin-6 in COPD-Related Pulmonary Hypertension, Chest, vol.136, pp.678-687, 2009.

C. Carlo, E. Raschi, R. Rezzonico, C. Testoni, R. Mallone et al., Autoantibodies to Fibroblasts Induce a Proadhesive and Proinflammatory Fibroblast Phenotype in Patients With Systemic Sclerosis, Arthritis & rheumatism, pp.1602-1613, 2002.

B. Christman, C. Mcpherson, J. Newman, G. King, G. Bernard et al., An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.70-75, 1992.
DOI : 10.1056/NEJM199207093270202

P. Dao, D. Montani, S. Duong-quy, and E. A. Dinh-xuan, Signalisation cellulaire et physiopathologie de l???hypertension art??rielle pulmonaire, Revue des Maladies Respiratoires, vol.23, issue.1, pp.3-75, 2006.
DOI : 10.1016/S0761-8425(06)73418-0

J. Morrell and . Wharton, ETA and ETB Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells, Am J Respir Crit Care Med, vol.165, pp.398-405, 2002.

B. Degano, L???hypertension art??rielle pulmonaire des connectivites, Revue des Maladies Respiratoires, vol.23, issue.6, pp.746-754, 2006.
DOI : 10.1016/S0761-8425(06)72088-5

. Kadowitz, Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1- pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor, J Pharmacol Exp Ther, vol.330, pp.334-341, 2009.

M. R. Hobbs, M. A. Wilkins, J. Gatzoulis, and . Wharton, Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.117, pp.3020-3030, 2008.

A. Dinh-xuan, Endothéline-1 et physiopathologie de l'hypertension artérielle pulmonaire, Revue des Maladies Respiratoires, vol.20, pp.6-121, 2003.

D. Peter, V. Zarka, I. Durand-gasselin, G. Monti, K. Balabanian et al., Frédérique Capron, Aurore Coulomb-lherminé, Chemokine RANTES in Severe Pulmonary Arterial Hypertension, pp.534-539, 2002.

O. Callaghan, G. Simonneau, F. Soubrier, and M. Humbert, Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation, American journal of respiratory and critical care medicine, pp.851-61, 2010.

H. Ines, K. Frei, R. Ramsebner, D. Doberer, V. Petkov et al., Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension, European Journal of Human Genetics, vol.15, pp.18-22, 2007.

S. A. Hamidi, R. Z. Lin, A. M. Szema, S. Lyubsky, Y. P. Jiang et al., VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension, Respiratory Research, vol.5, issue.1, p.141, 2011.
DOI : 10.1038/nrg1432

URL : http://doi.org/10.1186/1465-9921-12-141

R. E. Harrison, J. Flanagan, S. Sankelo, . Abdalla, R. Rowell et al., Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia, Journal of Medical Genetics, vol.40, issue.12, pp.865-871, 2003.
DOI : 10.1136/jmg.40.12.865

A. Hennette, Présentation et nouvelles approches thérapeutiques de l'Hypertension Artérielle Pulmonaire, Thèse pour obtenir le grade de docteur en Pharmacie, Faculté de Sciences Pharmaceutiques et Biologiques de Lille, p.138, 2005.

H. Marius, M. Michael, J. Krowka, P. Christian, and . Strassburg, Portopulmonary hypertension and hepatopulmonary syndrome, THE LANCET, vol.20, pp.8072-81, 2004.

F. Tapson, D. Torres, and D. A. Lawrence, Quinn et Hossein-Ardeschir Ghofrani, Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study, Circulation, vol.127, pp.1128-1138, 2013.

H. Marc, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib et al., Pulmonary Arterial Hypertension in France Results from a National Registry, American journal of respiratory and critical care medicine, pp.1023-1030, 2006.

I. Marc, C. Binkert, K. Morrison, W. Fischli, J. Gatfield et al., Pharmacology of Macitentan, an Orally Active Tissue- Targeting Dual Endothelin Receptor Antagonist, The journal of pharmacology and experimental therapeutics, pp.736-745, 2008.

J. Xavier, D. Launay, A. Yaici, J. L. Pavec, C. Tchérakian et al., Immunosuppressive Therapy in Lupus-and Mixed Connective Tissue Disease?Associated Pulmonary Arterial Hypertension A Retrospective Analysis of Twenty-Three Cases, Arthritis & rheumatism, pp.521-531, 2008.

M. M. Ghofrani, I. M. Hoeper, E. Lang, J. Mayer, L. Pepke-zaba et al., Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial, Journal of the American College of Cardiology, vol.52, pp.2127-2161, 2008.

J. Zhi-cheng, Z. Yu, J. Shen, B. Wu, K. Xu et al., Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study, American journal of respiratory and critical care medicine, pp.1723-1732, 2011.

H. I. Tracy, P. M. Palevsky, R. E. Hassoun, and . Girgis, A Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension, Circulation, vol.123, pp.2985-2993, 2011.

K. Risto, L. Grazette, R. Yacobi, C. Iliescu, R. Patten et al., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nature medicine, vol.12, pp.908-924, 2006.

N. H. Kim, Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?, European Respiratory Review, vol.19, issue.115, pp.68-71, 2010.
DOI : 10.1183/09059180.00007909

F. Ghofrani, A. E. Grimminger, S. Busch, and . Schäfer, Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling, Circulation, vol.118, pp.2081-2090, 2008.

K. Masataka, H. Watanabe, and N. Matsuoka, Naonobu Sugiyama, Pulmonary arterial hypertension associated with connective tissue disease : meta-analysis of clinical trials, BMJ Open, vol.3, p.3113, 2013.

K. Keiichi, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara, A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2- yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form The journal of pharmacology and experimental therapeutics, Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery, pp.4-691, 2008.

L. Tsung-ming, C. Chen, H. Shen, and N. Chang, Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension, Clinical Science, vol.116, pp.497-505, 2009.

H. H. Leuchte, C. Baezner, R. A. Baumgartner, D. Bevec, G. Bacher et al., Inhalation of vasoactive intestinal peptide in pulmonary hypertension, European Respiratory Journal, vol.32, issue.5, pp.1289-1294, 2008.
DOI : 10.1183/09031936.00050008

L. Thomas, F. Et, and M. Barton, Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs, Circulation, pp.2434-2440, 2000.

M. Vallerie, V. , A. Shillington, and S. Rich, Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy, Circulation, pp.1477-1482, 2002.

N. Mehta, I. Khan, R. Mehta, and D. Sepkowitz, HIV-Related Pulmonary Hypertension, Chest, vol.118, issue.4, pp.1133-1174, 2000.
DOI : 10.1378/chest.118.4.1133

M. Sandra, L. Peter, L. Jones, E. C. Martinez, and M. Rabinovitch, Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension, Circulation, pp.423-431, 2005.

M. Shoichi, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki et al., Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension Comparison with Cardiopulmonary Exercise Testing, American journal of respiratory and critical care medicine, pp.487-92, 2000.

D. Montani, X. Jaïs, O. Sitbon, F. Capron, G. Simonneau et al., Hypertension art??rielle pulmonaire, Revue des Maladies Respiratoires, vol.22, issue.4, pp.651-66, 2005.
DOI : 10.1016/S0761-8425(05)85616-5

D. Montani, L. C. Price, P. Dorfmuller, L. Achouh, X. Jaïs et al., Pulmonary veno-occlusive disease, European Respiratory Journal, vol.33, issue.1, pp.189-200, 2009.
DOI : 10.1183/09031936.00090608

URL : https://hal.archives-ouvertes.fr/inserm-01436297

D. Montani, C. Guignabert, F. Perros, and M. Humbert, Physiopathologie de l???hypertension art??rielle pulmonaire??: des progr??s et des attentes, Revue des Maladies Respiratoires, vol.29, issue.8, pp.950-952, 2012.
DOI : 10.1016/j.rmr.2012.08.006

M. David, M. Chaumais, C. Guignabert, S. Günther, B. Girerd et al., Targeted therapies in pulmonary arterial hypertension, Pharmacology & Therapeutics, vol.141, pp.172-191, 2014.

Y. A. Ratain, . Lussier, G. N. Joe, and . Garcia, Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension, pp.278-91, 2008.

K. T. Mouchaers, I. Schalij, M. A. De-boer, P. E. Postmus, V. W. Van-hinsbergh et al., Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil, European Respiratory Journal, vol.36, issue.4, pp.800-807, 2010.
DOI : 10.1183/09031936.00130209

D. Mukerjee, . St-george, C. Coleiro, C. Knight, . Denton et al., Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach, Annals of the Rheumatic Diseases, vol.62, issue.11, pp.1088-1093, 2003.
DOI : 10.1136/ard.62.11.1088

N. Tetsutaro, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki et al., Inhaled Rho Kinase Inhibitors Are Potent and SelectiveVasodilators in Rat Pulmonary Hypertension, Am J Respir Crit Care Med, vol.171, pp.494-499, 2005.

H. Siedentop and W. Seeger, Inhaled Iloprost for severe pulmonary hypertension, N Engl J Med, vol.347, pp.322-329, 2002.

G. Paciocco, F. J. Martinez, E. Bossone, E. Pielsticker, B. Gillespie et al., Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension, European Respiratory Journal, vol.17, issue.4, pp.647-652, 2001.
DOI : 10.1183/09031936.01.17406470

F. Perros and M. Humbert, Bases cellulaires et moléculaires de l'hypertension artérielle pulmonaire, Annales de Cardiologie et d'Angéiologie, pp.93-105, 2007.

G. Emilie, M. Simonneau, and . Humbert, Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension, Eur Respir J, vol.29, pp.462-468, 2007.

F. Perros, P. Dorfmüller, R. Souza, I. Durand-gasselin, V. Godot et al., Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension, European Respiratory Journal, vol.29, issue.5, pp.937-943, 2007.
DOI : 10.1183/09031936.00104706

P. Ventzislav, W. Mosgoeller, R. Ziesche, M. Raderer, L. Stiebellehner et al., Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, J. Clin. Invest, vol.111, pp.1339-1346, 2003.

P. Giuseppe, G. Frederique-capron, S. Stewart, O. Leone, M. Humbert et al., Pathologic Assessment of Vasculopathies in Pulmonary Hypertension, Journal of the American College of Cardiology, vol.43, pp.25-32, 2004.

P. Zlatko, I. Evangelos, D. Michelakis, M. S. Mcmurtry, B. Thébaud et al., In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats, Circulation, vol.107, pp.2037-2081, 2003.

J. J. Roberts, N. K. Mcelroy, N. C. Juskiw, S. Mallory, B. Rich et al., Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial Hypertension, The Journal of Heart and Lung Transplantation, vol.27, pp.668-74, 2008.

R. Christoph, R. Ewert, M. Halank, R. Wensel, H. Orzechowski et al., Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension, CHEST, vol.120, pp.1562-1569, 2001.

R. Lewis, J. David, B. Badesch, R. J. Barst, N. Galiè et al., Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, vol.346, pp.896-903, 2002.

S. Sami, I. Sayyed, A. Hamidi, K. G. Dickman, A. M. Szema et al., Waschek et Smadar Kort, Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene, Circulation, pp.1260-1268, 2007.

O. Sanchez, Physiopathologie de l'hypertension artérielle pulmonaire : rôle des facteurs vaso-actifs et de l'inflammation, thèse pour obtenir le grade de Docteur en Sciences de la Vie et de la Santé, p.134, 2010.

B. K. Sastry, C. Dm, D. Narasimhan, N. K. Reddy, D. et al., Clinical efficacy of sildenafil in primary pulmonary hypertension. A randomized, placebo-controlled, double-blind, crossover study, ACC Current Journal Review, vol.13, issue.6, pp.1149-53, 2004.
DOI : 10.1016/j.accreview.2004.06.025

N. Selimovic, C. Bergh, B. Andersson, E. Sakiniene, H. Carlsten et al., Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension, European Respiratory Journal, vol.34, issue.3, pp.662-668, 2009.
DOI : 10.1183/09031936.00174908

G. Semenza, Involvement of Hypoxia-Inducible Factor 1 in Pulmonary Pathophysiology, Chest, vol.128, issue.6, pp.592-594, 2005.
DOI : 10.1378/chest.128.6_suppl.592S

B. Seo, B. S. Oemar, R. Siebenmann, L. Segesser, and T. F. Lüscher, Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels, Circulation, vol.89, issue.3, pp.1203-1208, 1994.
DOI : 10.1161/01.CIR.89.3.1203

S. Patricia, N. Paul, L. M. Van-giersbergen, &. Halabi, and &. Jasper-dingemanse, Macitentan: entry-into-humans study with a new endothelin receptor antagonist, Eur J Clin Pharmacol, vol.67, pp.977-984, 2011.

A. Fishman, Clinical Classification of Pulmonary Hypertension, Journal of the American College of Cardiology, vol.43, pp.5-12, 2004.

S. Gérald, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix et al., Updated Clinical Classification of Pulmonary Hypertension, Journal of the American College of Cardiology, vol.54, pp.43-54, 2009.

S. Gérald, A. Torbicki, M. M. Hoeper, M. Delcroix, K. Karlocai et al., Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension, Eur Respir J, vol.40, pp.874-880, 2012.

H. Machado, I. M. Olschewski, R. Robbins, and . Souza, Updated Clinical Classification of Pulmonary Hypertension, Journal of the American College of Cardiology, vol.62, pp.34-41, 2013.

S. Olivier, M. Humbert, H. Nunes, F. Parent, G. Garcia et al., Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension, Prognostic Factors and Survival, Journal of the American College of Cardiology, vol.40, pp.780-788, 2002.

M. Steiner, O. L. Kathryn, N. Syrkina, E. J. Kolliputi, C. A. Mark et al., Interleukin-6 overexpression induces pulmonary hypertension Circ Res, pp.236-244, 2009.

V. Durand, D. , and C. L. Jeunne, Dorosz, Guide pratique des médicaments 33 ème édition, 2014.

M. Vogel, F. Berger, A. Kramer, V. Alexi-meshkishvili, and P. E. Lange, Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects, Heart, vol.82, issue.1, pp.30-33, 1999.
DOI : 10.1136/hrt.82.1.30

W. Martin, R. , O. Ali, W. Bradlow, J. Wharton et al., Gibbs; for the Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group, Simvastatin as a Treatment for Pulmonary Hypertension Trial, American journal of respiratory and critical care medicine, Petros Nihoyannopoulos, Raad H. Mohiaddin, and J. Simon R, vol.181, pp.1106-1113, 2010.

A. M. Yuan-jason-xiao-jian, M. Aldinger, J. Juhaszova, J. V. Wang, S. P. Conte-jr et al., Dysfunctional Voltage-Gated K+ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension, Circulation, vol.98, issue.14, pp.1400-1406, 1998.
DOI : 10.1161/01.CIR.98.14.1400

D. Zhao-yidan, W. David, Y. Courtman, L. Deng, Q. Kugathasan et al., Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow-Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease, Circulation Research, vol.96, issue.4, pp.442-450, 2005.
DOI : 10.1161/01.RES.0000157672.70560.7b

D. Dubois and C. Pharmacologie, 3 ème année de pharmacie, « Transmissions adrénergiques, 2014.